Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Stat...(futureplans events or performance are fo...)

Date:11/11/2008

future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, the effect of a potential delisting of our common stock from The Nasdaq Global Market, uncertainty regarding potential future deterioration in the market for auction rate securities which could negatively affect our cash position and result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

'/>"/>

SOURCE deCODE genetics Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
3. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
4. Genzyme Begins Major Expansion of Boston Manufacturing Facility
5. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
6. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
7. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
8. National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center
9. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
10. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
11. SPO Medical Announces Major Sales Milestone